ArticleThe oncologist2025
Real-world treatment patterns and outcomes of patients with hormone receptor-positive/HER2-low metastatic breast cancer treated with chemotherapy.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionHormonal therapy (HT) based regimen is the preferred first-line (1L) treatment for hormone receptor-positive (HR+) metastatic breast cancer (mBC) with human receptor epidermal growth factor 2 (HER2)-low expression. However, HT resistance frequently emerges with many receiving subsequent chemotherapy (CT). This study aimed to examine CT treatment patterns and outcomes among patients with HR+/HER2-low mBC. PATIENTS AND
methodsPatient characteristics and clinical data of adults receiving CT for HR+/HER2-low mBC were collected via physician-abstracted chart review from 10/1/2021 to 1/31/2022. Data were summarized using descriptive statistics with the Kaplan-Meier method to estimate time-to-event outcomes. Statistical comparisons were conducted between patients who received 1L CT vs CT after HT-based regimens (any line).
resultsTwo hundred and twenty three HR+/HER2-low patients were included, and CT utilization was described by line within metastatic setting: 1L = 20.2% (n = 45), 2L 26.4% (n = 59), 3L+ = 53.4% (n = 119). A higher rate of visceral metastases (86.7% vs 65.7%, P = .01) and lower Eastern Cooperative Oncology Group (ECOG) score (88.9% vs 70.2%, P = 0.01) were associated with 1L CT vs CT post-HT-based treatment. The median time-to-treatment discontinuation (TTD) and real-world progression free survival (rwPFS) of CT were similar between the groups (TTD: 6.7 months vs 8.3 months for the 1L CT and CT post-HT-based regimen groups, respectively, P = .13; rwPFS: 9.3 months vs 8.8 months, P = .26).
conclusionIn this sample of HR+/HER2-low mBC patients, most patients switched to CT after two lines of therapy with a median rwPFS shorter than 10 months. The findings highlight unmet needs for a more effective targeted therapeutic alternative to CT for HR+/HER2-low mBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.